Genmab A/S at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, and good afternoon. I'm James Gordon, JPMorgan European Pharma and Biotech analyst. And today, at the JPMorgan Conference, I have the pleasure of introducing the Genmab presentation and Q&A. So Genmab President and CEO, Jan van de Winkel, joining us for a 20-minute presentation, and then we're going to do 20 minutes of Q&A.
And so with that said, thanks a lot for joining us today, Jan, and over to you for the presentation.
/-- -
Thanks, James, for the introduction. It's a pleasure to be with you all again at the Annual JPMorgan Healthcare Conference as we kick off 2022. Slides from today's presentation will be available for download on our website immediately after the event. So let's get started.
Next slide, please. I'm now on Slide #2. This presentation may contain forward-looking statements and as such may contain
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |